UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for eczema and atopic dermatitis in the United Kingdom. Explore treatment pathways including biologics, JAK inhibitors, and topical therapies.
Atopic dermatitis (eczema) affects up to 15 million people in the UK, with ~10% adults and 20% children affected. Moderate-to-severe atopic dermatitis significantly impacts quality of life with persistent itching, pain, sleep disruption, and skin infections. It is driven by immune system dysfunction involving type 2 inflammation (IL-4, IL-13, IL-31 pathways).
Mild eczema: emollients and topical corticosteroids. Moderate: topical calcineurin inhibitors (tacrolimus), crisaborole. Moderate-to-severe: dupilumab (IL-4/IL-13 blocker, first biologic approved), tralokinumab, baricitinib (JAK inhibitor), upadacitinib (JAK inhibitor), abrocitinib. Newer biologics targeting IL-31 (nemolizumab) and IL-22 are expanding options.
The eczema treatment landscape has been revolutionised by biologics and JAK inhibitors. Dupilumab transformed care for moderate-to-severe patients. JAK inhibitors (upadacitinib, abrocitinib) offer even faster clearance but with additional monitoring requirements. Novel approaches in trials include: topical JAK inhibitors (ruxolitinib cream), IL-31 receptor antagonists, microbiome-based therapies, and personalized treatment based on biomarker profiles.
The UK has active eczema/atopic dermatitis trial programmes at major dermatology centres. Current research includes: next-generation biologics, oral small molecules, novel topical agents, combination therapies, and long-term safety studies. Many trials offer access to treatments before NHS availability. Paediatric eczema trials are also widely available.
Free AI-powered matching - no signup required
Search atopic dermatitis Trials →